AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

NASDAQ:FIXXHomology Medicines Competitors & Alternatives

$16.59
+1.23 (+8.01 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.23
Now: $16.59
$16.73
50-Day Range
$13.32
MA: $15.39
$16.58
52-Week Range
$11.05
Now: $16.59
$24.00
Volume1.06 million shs
Average Volume361,405 shs
Market Capitalization$750.08 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04

Competitors

Homology Medicines (NASDAQ:FIXX) Vs. INSM, KRTX, OPK, TARO, AMRN, and TGTX

Should you be buying FIXX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Homology Medicines, including Insmed (INSM), Karuna Therapeutics (KRTX), Opko Health (OPK), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), and TG Therapeutics (TGTX).

Insmed (NASDAQ:INSM) and Homology Medicines (NASDAQ:FIXX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Institutional & Insider Ownership

95.5% of Insmed shares are owned by institutional investors. Comparatively, 81.9% of Homology Medicines shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Comparatively, 28.0% of Homology Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Insmed has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Profitability

This table compares Insmed and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insmed-162.82%-87.35%-33.04%
Homology Medicines-5,816.28%-44.92%-36.71%

Earnings and Valuation

This table compares Insmed and Homology Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$136.47 million21.02$-254,340,000.00($3.01)-9.43
Homology Medicines$1.67 million449.15$-103,920,000.00($2.47)-6.72

Homology Medicines has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Insmed and Homology Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insmed00803.00
Homology Medicines00803.00

Insmed currently has a consensus target price of $42.00, suggesting a potential upside of 47.94%. Homology Medicines has a consensus target price of $32.6250, suggesting a potential upside of 96.65%. Given Homology Medicines' higher possible upside, analysts plainly believe Homology Medicines is more favorable than Insmed.

Summary

Homology Medicines beats Insmed on 7 of the 12 factors compared between the two stocks.

Karuna Therapeutics (NASDAQ:KRTX) and Homology Medicines (NASDAQ:FIXX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Institutional & Insider Ownership

63.9% of Karuna Therapeutics shares are owned by institutional investors. Comparatively, 81.9% of Homology Medicines shares are owned by institutional investors. 18.1% of Karuna Therapeutics shares are owned by company insiders. Comparatively, 28.0% of Homology Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Karuna Therapeutics and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karuna TherapeuticsN/A-18.24%-15.83%
Homology Medicines-5,816.28%-44.92%-36.71%

Earnings and Valuation

This table compares Karuna Therapeutics and Homology Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-27.22
Homology Medicines$1.67 million449.15$-103,920,000.00($2.47)-6.72

Karuna Therapeutics has higher earnings, but lower revenue than Homology Medicines. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Karuna Therapeutics and Homology Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karuna Therapeutics001103.00
Homology Medicines00803.00

Karuna Therapeutics currently has a consensus target price of $117.7273, suggesting a potential upside of 17.52%. Homology Medicines has a consensus target price of $32.6250, suggesting a potential upside of 96.65%. Given Homology Medicines' higher possible upside, analysts plainly believe Homology Medicines is more favorable than Karuna Therapeutics.

Summary

Karuna Therapeutics beats Homology Medicines on 6 of the 11 factors compared between the two stocks.

Opko Health (NASDAQ:OPK) and Homology Medicines (NASDAQ:FIXX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Earnings and Valuation

This table compares Opko Health and Homology Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opko Health$901.90 million3.03$-314,920,000.00($0.41)-9.95
Homology Medicines$1.67 million449.15$-103,920,000.00($2.47)-6.72

Homology Medicines has lower revenue, but higher earnings than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Opko Health has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Opko Health and Homology Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opko Health00303.00
Homology Medicines00803.00

Opko Health currently has a consensus target price of $4.1667, suggesting a potential upside of 2.12%. Homology Medicines has a consensus target price of $32.6250, suggesting a potential upside of 96.65%. Given Homology Medicines' higher possible upside, analysts plainly believe Homology Medicines is more favorable than Opko Health.

Institutional & Insider Ownership

23.7% of Opko Health shares are owned by institutional investors. Comparatively, 81.9% of Homology Medicines shares are owned by institutional investors. 40.9% of Opko Health shares are owned by company insiders. Comparatively, 28.0% of Homology Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Opko Health and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Opko Health-32.92%-13.56%-9.43%
Homology Medicines-5,816.28%-44.92%-36.71%

Summary

Opko Health beats Homology Medicines on 7 of the 13 factors compared between the two stocks.

Homology Medicines (NASDAQ:FIXX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares Homology Medicines and Taro Pharmaceutical Industries' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Homology Medicines$1.67 million449.15$-103,920,000.00($2.47)-6.72
Taro Pharmaceutical Industries$644.77 million3.90$244.24 million$6.3510.36

Taro Pharmaceutical Industries has higher revenue and earnings than Homology Medicines. Homology Medicines is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Homology Medicines has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Homology Medicines and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Homology Medicines00803.00
Taro Pharmaceutical Industries00103.00

Homology Medicines currently has a consensus target price of $32.6250, suggesting a potential upside of 96.65%. Taro Pharmaceutical Industries has a consensus target price of $96.00, suggesting a potential upside of 45.87%. Given Homology Medicines' higher possible upside, equities research analysts clearly believe Homology Medicines is more favorable than Taro Pharmaceutical Industries.

Institutional and Insider Ownership

81.9% of Homology Medicines shares are owned by institutional investors. Comparatively, 11.6% of Taro Pharmaceutical Industries shares are owned by institutional investors. 28.0% of Homology Medicines shares are owned by company insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Homology Medicines and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Homology Medicines-5,816.28%-44.92%-36.71%
Taro Pharmaceutical Industries37.88%11.94%10.79%

Summary

Taro Pharmaceutical Industries beats Homology Medicines on 8 of the 13 factors compared between the two stocks.

Homology Medicines (NASDAQ:FIXX) and Amarin (NASDAQ:AMRN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares Homology Medicines and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Homology Medicines$1.67 million449.15$-103,920,000.00($2.47)-6.72
Amarin$429.76 million6.07$-22,650,000.00($0.07)-96.71

Amarin has higher revenue and earnings than Homology Medicines. Amarin is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Homology Medicines has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Homology Medicines and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Homology Medicines00803.00
Amarin05802.62

Homology Medicines currently has a consensus target price of $32.6250, suggesting a potential upside of 96.65%. Amarin has a consensus target price of $17.2308, suggesting a potential upside of 154.52%. Given Amarin's higher possible upside, analysts clearly believe Amarin is more favorable than Homology Medicines.

Institutional and Insider Ownership

81.9% of Homology Medicines shares are owned by institutional investors. Comparatively, 44.4% of Amarin shares are owned by institutional investors. 28.0% of Homology Medicines shares are owned by company insiders. Comparatively, 2.8% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Homology Medicines and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Homology Medicines-5,816.28%-44.92%-36.71%
Amarin-3.67%-4.05%-2.45%

Summary

Amarin beats Homology Medicines on 8 of the 13 factors compared between the two stocks.

Homology Medicines (NASDAQ:FIXX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares Homology Medicines and TG Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Homology Medicines$1.67 million449.15$-103,920,000.00($2.47)-6.72
TG Therapeutics$150,000.0017,524.06$-172,870,000.00($1.83)-13.04

Homology Medicines has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Homology Medicines has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Homology Medicines and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Homology Medicines00803.00
TG Therapeutics00403.00

Homology Medicines currently has a consensus target price of $32.6250, suggesting a potential upside of 96.65%. TG Therapeutics has a consensus target price of $41.00, suggesting a potential upside of 71.84%. Given Homology Medicines' higher possible upside, equities research analysts clearly believe Homology Medicines is more favorable than TG Therapeutics.

Institutional and Insider Ownership

81.9% of Homology Medicines shares are owned by institutional investors. Comparatively, 58.9% of TG Therapeutics shares are owned by institutional investors. 28.0% of Homology Medicines shares are owned by company insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Homology Medicines and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Homology Medicines-5,816.28%-44.92%-36.71%
TG Therapeutics-124,230.27%-2,937.74%-155.97%

Summary

Homology Medicines beats TG Therapeutics on 10 of the 13 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Insmed logo
INSM
Insmed
1.5$28.39+2.6%$2.90 billion$136.47 million-10.07Analyst Upgrade
KRTX
Karuna Therapeutics
1.5$100.18+0.7%$2.64 billionN/A-0.68Increase in Short Interest
Opko Health logo
OPK
Opko Health
1.7$4.08+6.1%$2.63 billion$901.90 million-8.50Analyst Report
Increase in Short Interest
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$65.81+1.7%$2.61 billion$644.77 million10.35Decrease in Short Interest
Amarin logo
AMRN
Amarin
1.8$6.77+0.4%$2.59 billion$429.76 million-112.83
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$23.86+5.2%$2.49 billion$150,000.00-11.75Analyst Downgrade
Heavy News Reporting
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$30.97+0.5%$2.33 billionN/A-4.93Increase in Short Interest
Heavy News Reporting
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$56.54+4.2%$2.29 billion$421.03 million-2,825.59Analyst Report
TPTX
Turning Point Therapeutics
1.4$61.85+1.5%$2.25 billionN/A-17.18
SAGE Therapeutics logo
SAGE
SAGE Therapeutics
1.6$44.40+5.5%$2.20 billion$6.87 million-3.57Heavy News Reporting
IGMS
IGM Biosciences
1.5$72.17+2.1%$2.17 billionN/A-15.04Analyst Downgrade
Uniqure logo
QURE
Uniqure
1.7$46.82+2.3%$1.99 billion$7.28 million-15.55Analyst Downgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.84+1.5%$1.91 billion$306.49 million19.14
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$25.74+0.2%$1.91 billion$23.90 million-15.23Insider Selling
Decrease in Short Interest
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$49.24+1.0%$1.88 billion$26.69 million-37.30Analyst Upgrade
Heavy News Reporting
Principia Biopharma logo
PRNB
Principia Biopharma
1.4$56.38+0.8%$1.88 billion$35.16 million-23.11Analyst Report
Xencor logo
XNCR
Xencor
1.6$32.95+1.1%$1.87 billion$156.70 million-30.79Heavy News Reporting
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.8$36.24+0.9%$1.82 billion$963.01 million13.04Increase in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$111.97+1.9%$1.77 billion$120.28 million-32.55Analyst Downgrade
Unusual Options Activity
Heavy News Reporting
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$15.61+2.1%$1.74 billion$320,000.00-11.92Analyst Downgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$19.34+0.9%$1.74 billionN/A-5.74Analyst Report
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.5$13.03+0.0%$1.73 billion$335 million-5.90Analyst Upgrade
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.3$41.60+2.5%$1.70 billionN/A-16.71
Zymeworks logo
ZYME
Zymeworks
1.7$37.28+3.6%$1.69 billion$29.54 million-9.58Increase in Short Interest
Heavy News Reporting
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$110.00+1.4%$1.69 billionN/A-16.15Analyst Downgrade
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.5$25.05+3.0%$1.64 billion$60,000.00-9.01Analyst Downgrade
Unusual Options Activity
Heavy News Reporting
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.16+1.1%$1.64 billion$428.41 million19.17Analyst Downgrade
Heavy News Reporting
Epizyme logo
EPZM
Epizyme
1.6$16.25+0.7%$1.60 billion$23.80 million-8.00Analyst Downgrade
ZNTL
Passage Bio
1.1$42.54+0.3%$1.58 billionN/A0.00
IMAB
I-Mab
1.2$29.50+0.2%$1.57 billion$4.31 million-1.02Heavy News Reporting
Cytokinetics logo
CYTK
Cytokinetics
1.4$26.92+3.3%$1.55 billion$26.87 million-12.02Analyst Upgrade
Insider Selling
Decrease in Short Interest
Heavy News Reporting
MacroGenics logo
MGNX
MacroGenics
1.3$31.51+3.6%$1.53 billion$64.19 million-10.20Increase in Short Interest
Zogenix logo
ZGNX
Zogenix
2.0$27.58+5.4%$1.53 billion$3.65 million-2.92
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$22.85+2.1%$1.49 billion$42.12 million-16.32
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$44.05+3.0%$1.48 billion$252 million-4.11
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.3$26.08+2.0%$1.47 billion$410,000.00-6.59Analyst Upgrade
ZEALAND PHARMA/S logo
ZEAL
ZEALAND PHARMA/S
0.8$36.96+0.3%$1.47 billion$6.20 million-13.69
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.8$19.48+2.0%$1.43 billion$40.89 million-6.67
Akcea Therapeutics logo
AKCA
Akcea Therapeutics
1.2$14.05+0.6%$1.43 billion$488.54 million-46.83Analyst Downgrade
Portola Pharmaceuticals logo
PTLA
Portola Pharmaceuticals
1.5$18.03+0.0%$1.42 billion$116.64 million-4.78
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$52.71+3.2%$1.40 billion$148.36 million-5.47Increase in Short Interest
Innoviva logo
INVA
Innoviva
0.9$13.62+0.1%$1.40 billion$261.02 million7.96Analyst Downgrade
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.4$23.27+1.8%$1.37 billionN/A-10.43
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.6$15.01+0.3%$1.36 billion$145.97 million-6.61
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$4.51+0.7%$1.35 billion$1.63 billion-2.80
ARVN
Arvinas
1.6$33.93+1.6%$1.33 billion$42.98 million-15.35Analyst Downgrade
Increase in Short Interest
Tricida logo
TCDA
Tricida
2.0$26.93+0.7%$1.33 billionN/A-6.26Analyst Downgrade
Increase in Short Interest
Heavy News Reporting
Odonate Therapeutics logo
ODT
Odonate Therapeutics
1.0$38.88+0.6%$1.27 billionN/A-9.89Analyst Downgrade
Heavy News Reporting
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.5$21.16+2.5%$1.26 billion$73.41 million-4.88Analyst Report
Increase in Short Interest
Heavy News Reporting
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$23.38+1.4%$1.24 billion$392.76 million10.77Analyst Downgrade
Heavy News Reporting
This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.